Low-grade gliomas (LGGs) are a heterogenous group of primary brain neoplasms that most commonly occur in children and young adults, characterized by a slow, indolent course and overall favorable prognosis. Standard therapies used to treat LGGs have included surgical resection, radiotherapy, chemotherapy, or a combination thereof. Given the anticipated long survival and typical young age of patients with LGG, the long-term sequelae of therapy require special attention, especially as they affect neurocognitive function and quality of life. We review the complex interplay of baseline and treatment-related factors that perturb neurocognition as well as the effect of each treatment modality on altering neurocognitive outcomes in this patient population.
Copyright © 2015 Elsevier Inc. All rights reserved.